Application and Prospect of CRISPR/Cas9 Technology in Reversing Drug Resistance of Non-Small Cell Lung Cancer

Lu Huang; Zhi Liao; Zhixi Liu; Yan Chen; Tingwenli Huang; Hongtao Xiao

doi:10.3389/fphar.2022.900825

Application and Prospect of CRISPR/Cas9 Technology in Reversing Drug Resistance of Non-Small Cell Lung Cancer

Front Pharmacol. 2022 May 10:13:900825. doi: 10.3389/fphar.2022.900825. eCollection 2022.

Authors

Lu Huang^{1

2}, Zhi Liao³, Zhixi Liu^{1

2}, Yan Chen¹, Tingwenli Huang^{1

2}, Hongtao Xiao^{1

2}

Affiliations

¹ Department of Clinical Pharmacy, Sichuan Cancer Center, School of Medicine, Sichuan Cancer Hospital and Institute, University of Electronic Science and Technology of China, Chengdu, China.
² Personalized Drug Therapy Key Laboratory of Sichuan Province, Chengdu, China.
³ Department of Gynecology and Obstetrics, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu, China.

Abstract

Cancer drug resistance has always been a major factor affecting the treatment of non-small cell lung cancer, which reduces the quality of life of patients. The clustered regularly interspaced short palindromic repeats/CRISPR associated protein 9 (CRISPR/Cas9) technology, as an efficient and convenient new gene-editing technology, has provided a lot of help to the clinic and accelerated the research of cancer and drug resistance. In this review, we introduce the mechanisms of drug resistance in non-small cell lung cancer (NSCLC), discuss how the CRISPR/Cas9 system can reverse multidrug resistance in NSCLC, and focus on drug resistance gene mutations. To improve the prognosis of NSCLC patients and further improve patients' quality of life, it is necessary to utilize the CRISPR/Cas9 system in systematic research on cancer drug resistance.

Keywords: CRISPR/Cas9; TKIs; drug resistance; gene editing; non-small cell lung cancer.

Publication types

Review